See the published version of this article at BMC Pulmonary Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Prognostic significance of serum osteopontin levels in small-cell lung cancer
Chunhua Xu
Nanjing Chest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8728-2183
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Keywords
Small-cell lung cancer, Osteopontin, biomarker, treatment responses, overall survival
Figure 1
Figure 2
Figure 3
chunhua Xu
commented on 21 January, 2020
In this work, the OPN levels were analyzed using ELISA in 96 SCLC patients before and after first-line chemotherapy and 60 healthy controls. The pre-treatment levels of serum OPN in SCLC patients were higher than those of healthy controls. Pre-treatment levels of serum OPN were significantly associated with disease stage, tumor size and lymph node metastasis. After treatment with the first-line chemotherapy, the post-treatment levels of serum OPN were obviously decreased, and correlated with treatment responses, although there was no significant difference in their pretreatment OPN levels. Cox proportional hazard analysis demonstrated that the post-treatment levels of serum OPN, disease stage and PS status were all independent predictors for overall survival of patients. The results from the current study indicate that serum level of OPN could be further confirmed as a biomarker to predict treatment responses and survival of SCLC patients.
1 comment flagged for moderation
If you posted a comment and think it was mistakenly removed, please contact customer support at [email protected].
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 1
Posted 13 Jan, 2020
Published
On 01 Sep, 2020
Published
On 01 Sep, 2020
Community comments: 1
Editorial decision: Minor revision
On 04 Jun, 2020
Review #2 received
Received 17 Feb, 2020
Review #1 received
Received 17 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Reviewer #1 agreed
On 03 Feb, 2020
Editor assigned
On 27 Jan, 2020
Submission checks complete
On 10 Jan, 2020
Editor invited
On 10 Jan, 2020
First submitted
On 26 Dec, 2019
Metrics
Comments: 1
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Pulmonary Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Prognostic significance of serum osteopontin levels in small-cell lung cancer
Chunhua Xu
Nanjing Chest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8728-2183
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Version 1
Posted 13 Jan, 2020
Published
On 01 Sep, 2020
Published
On 01 Sep, 2020
Community comments: 1
Editorial decision: Minor revision
On 04 Jun, 2020
Review #2 received
Received 17 Feb, 2020
Review #1 received
Received 17 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewers invited
Invitations sent on 03 Feb, 2020
Reviewer #1 agreed
On 03 Feb, 2020
Editor assigned
On 27 Jan, 2020
Submission checks complete
On 10 Jan, 2020
Editor invited
On 10 Jan, 2020
First submitted
On 26 Dec, 2019
Metrics
Comments: 1
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Backgroud
Osteopontin (OPN) is involved in the development and metastasis of a variety of tumors. This study explored serum OPN levels in patients with small cell lung cancer (SCLC) and compared them with healthy controls.
Methods
The OPN levels of 96 patients with SCLC before and after first-line chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA) and compared with 60 healthy controls.
Results
The pre-treatment serum OPN levels of patients with SCLC were higher than those of healthy controls (P<0.001). Serum OPN levels were significantly associated with disease stage, tumor size, and lymph node metastasis (P=0.012, 0.034, and 0.037, respectively). Serum OPN levels were significantly decreased after first-line chemotherapy (P=0.019), which was associated with treatment response (P=0.011), but there was no significant difference with pre-treatment OPN levels (P=0.485). Cox proportional hazard analysis showed that serum OPN levels, disease stage, and performance status were independent predictors of overall survival.
Conclusions
Our results suggest that serum OPN levels can be used as biomarkers to predict treatment response and survival in patients with SCLC.
Figure 1
Figure 2
Figure 3
chunhua Xu
commented on 21 January, 2020
In this work, the OPN levels were analyzed using ELISA in 96 SCLC patients before and after first-line chemotherapy and 60 healthy controls. The pre-treatment levels of serum OPN in SCLC patients were higher than those of healthy controls. Pre-treatment levels of serum OPN were significantly associated with disease stage, tumor size and lymph node metastasis. After treatment with the first-line chemotherapy, the post-treatment levels of serum OPN were obviously decreased, and correlated with treatment responses, although there was no significant difference in their pretreatment OPN levels. Cox proportional hazard analysis demonstrated that the post-treatment levels of serum OPN, disease stage and PS status were all independent predictors for overall survival of patients. The results from the current study indicate that serum level of OPN could be further confirmed as a biomarker to predict treatment responses and survival of SCLC patients.